Researchers have now identified three new molecular drug targets in Naegleria fowleri and a number of drugs that are able to inhibit the amoeba's growth in a laboratory dish. Several of these drugs are already approved by the US Food and Drug Administration for other uses, such as antifungal agents, the breast cancer drug tamoxifen and antidepressant Prozac.